Dr. Matthew B. Klein is the CEO of PTC Therapeutics, where he took the helm in March 2023 after joining the company in 2019. Before becoming CEO, he held various leadership roles, including Chief Operating Officer and Chief Development Officer....
Dr. Matthew B. Klein is the CEO of PTC Therapeutics, where he took the helm in March 2023 after joining the company in 2019. Before becoming CEO, he held various leadership roles, including Chief Operating Officer and Chief Development Officer. His educational background is impressive: he has a BA from the University of Pennsylvania, an MD from Yale, and an MS in Epidemiology from the University of Washington. Dr. Klein's career has included significant roles at BioElectron, where he was the CEO and Chief Medical Officer before he joined PTC. Under his leadership, PTC Therapeutics is focusing on the development of innovative treatments, leveraging his extensive experience in clinical development and regulatory strategies. Interestingly, in 2023, his total compensation reached about $8.94 million, which reflects his position and the responsibilities he handles. The structure of his pay is aligned with the company’s performance, ensuring that he is invested in the firm's success. Dr. Klein is also involved on the board of ClearPoint Neuro, enriching his experience in the biotech field as he guides PTC to new heights in therapeutic solutions.